Most researchers who arrive at tesamorelin arrive the same way: they read the Stanley or Falutz papers, notice the effect size on visceral adipose tissue (VAT) and liver fat, and realize this is not a molecule with anecdotal roots — it has a randomized controlled trial record. The problem is that most online resources either repeat basic pharmacology without practical depth, or skip the science entirely and just push product. This guide does neither. It is written for the first-time investigator in the UAE who wants both: a real understanding of what they are working with, and a clear path to buy tesamorelin UAE from a supplier who takes cold-chain and purity as seriously as the research does.
Tesamorelin (INN: tesamorelin acetate) is a synthetic analog of endogenous growth-hormone-releasing hormone (GHRH 1-44). The native GHRH peptide is 44 amino acids long and is rapidly cleaved by dipeptidyl peptidase-IV (DPP-IV) in plasma, giving it a half-life of a few minutes. Tesamorelin adds a trans-3-hexenoyl fatty-acid modification to the N-terminus — a change that blocks the DPP-IV cleavage site, extending plasma half-life to roughly 26-38 minutes while preserving the full pharmacology of native GHRH at the pituitary receptor.
The result is a molecule that stimulates the somatotroph cells of the anterior pituitary to release growth hormone in a pulsatile pattern — not a supraphysiological flood, but the kind of rhythmic GH secretion the hypothalamus normally drives. This matters because pulsatile GH is the signal the liver responds to with IGF-1 production, and it is also the pattern that drives selective lipolysis in visceral adipose depots without the same glucose-interference signal that continuous GH infusion produces. Tesamorelin does not directly burn fat; it corrects the pituitary output that regulates how fat is distributed and metabolized.
Visceral adipose tissue (VAT) — the fat packed around intra-abdominal organs — has a much higher density of GH receptors and lipolytic responsiveness than subcutaneous fat. When GH secretion declines (with age, metabolic dysfunction, or HIV-associated lipodystrophy), VAT accumulates disproportionately. Tesamorelin, by restoring pulsatile GH, preferentially mobilizes VAT. This is the mechanistic reason the clinical trials showed selective visceral remodeling without equivalent subcutaneous fat loss.
Before running any research protocol, an investigator needs to understand what the peer-reviewed record looks like. Tesamorelin has four major published RCTs — more than almost any peptide currently available to researchers in the UAE. Here is what each found:
| Study | Journal | N | Dose | Duration | Key Outcome |
|---|---|---|---|---|---|
| Falutz et al. 2007 | NEJM | 412 | 2 mg/day SC | 26 weeks | VAT -15 to -18% vs placebo; IGF-1 +~50% |
| Falutz et al. 2010 | J Clin Endocrinol Metab | 412 (extension) | 2 mg/day SC | 52 weeks total | VAT reduction maintained; liver fat trend noted |
| Stanley et al. 2014 | JAMA | HIV-NAFLD cohort | 2 mg/day SC | 12 months | Liver fat -32% vs placebo by MRS |
| Stanley et al. 2019 | Lancet HIV | HIV-NAFLD cohort | 2 mg/day SC | 12 months | NAFLD improvement confirmed; sustained lipid effects |
Three points every first-time investigator should internalize from this table. First, the effect sizes are large by peptide standards — a 15-18% reduction in VAT and 32% reduction in liver fat are not marginal signals. Second, every single trial used 2 mg/day subcutaneous dosing, establishing this as the anchor research-context reference dose. Third, the duration was 26 weeks minimum in every study — this is not a molecule where investigators expect to see meaningful endpoints in two weeks. Cycle design matters.
REVIVE LAB UAE stocks tesamorelin in two formats: 5 mg and 10 mg lyophilized vials. These map directly to the dosing architecture used in the published trials and allow investigators to choose based on cycle length and reconstitution preference.
The reconstitution volume you choose sets your concentration, which determines how much you draw for a given research-context dose. The table below shows the most common configurations. For the 2 mg/day research reference dose used in the Falutz and Stanley trials, a 5 mg vial reconstituted in 1 mL gives a 5 mg/mL concentration — meaning 0.4 mL per administration, or 40 IU on a standard U-100 insulin syringe.
| Vial | BAC Water Added | Concentration | Volume for 1 mg dose | Volume for 2 mg dose |
|---|---|---|---|---|
| Tesamorelin 5 mg | 1 mL | 5 mg/mL | 0.2 mL (20 IU) | 0.4 mL (40 IU) |
| Tesamorelin 5 mg | 2 mL | 2.5 mg/mL | 0.4 mL (40 IU) | 0.8 mL (80 IU) |
| Tesamorelin 10 mg | 2 mL | 5 mg/mL | 0.2 mL (20 IU) | 0.4 mL (40 IU) |
| Tesamorelin 10 mg | 4 mL | 2.5 mg/mL | 0.4 mL (40 IU) | 0.8 mL (80 IU) |
For first-time observers, the 5 mg vial with 1 mL reconstitution is the cleanest arithmetic. A single 5 mg vial supports 2.5 days at 2 mg/day or 5 days at 1 mg/day. Most investigators running a 12-week observational window at 2 mg/day will need approximately 168 mg total — around 17 x 10 mg vials or 34 x 5 mg vials. REVIVE LAB UAE bundles are structured to support full-cycle ordering.
Tesamorelin is supplied as a lyophilized (freeze-dried) white powder. Before any research observation can proceed, investigators must reconstitute the vial with bacteriostatic water (BAC water). This process is straightforward but requires care — the peptide chain is fragile when transitioning from dry to solution form, and aggressive agitation causes aggregation that reduces potency.
Keep reconstituted vials at 2-8°C, protected from light. Do not freeze reconstituted vials — freeze-thaw cycles disrupt peptide tertiary structure and are irreversible. Lyophilized (unreconstituted) vials from REVIVE LAB UAE are stable for 30+ days refrigerated and have a longer shelf life if kept frozen before use.
The Falutz 2007 trial ran 26 weeks to document VAT changes. But a well-structured 12-week observational window can capture early IGF-1 response data and VAT trends — particularly if the investigator establishes clear baseline measurements before the cycle begins. Here is a framework that mirrors the methodological structure of the published research without adapting it as personal advice.
Responsible research always begins with baseline documentation. In the Falutz and Stanley trials, this meant DEXA or CT for VAT quantification, MRS for liver fat, and fasting metabolic panel including IGF-1. In a research-context observational design, investigators typically document:
The Falutz data showed IGF-1 elevation beginning within the first 2-4 weeks at 2 mg/day — a rise of approximately 50% from baseline in the active group versus placebo. Early in the observational window, investigators note whether IGF-1 is responding. VAT changes are not expected to be perceptible in the first month; this phase is about establishing the GH pulse and monitoring early biomarker response. Dosing is typically administered once daily in the morning, subcutaneous, in the research protocols used by Falutz and Stanley.
By weeks 5-8, investigators in the published trials were seeing sustained IGF-1 elevation and early signals in body composition metrics. In a 12-week window, this is the phase where mid-cycle IGF-1 can be re-checked against baseline. The Stanley 2014 JAMA trial was structured on 12-month data, but interim imaging at 6 months showed approximately 18% liver fat reduction by the midpoint — proportional scaling would suggest measurable but not full-magnitude effects at 12 weeks in a shorter observational design.
At cycle close, investigators repeat the baseline panel: IGF-1, fasting glucose, liver enzymes, body composition proxy metrics. This gives a comparable before/after data set that mirrors the methodological structure of the published literature. In the Falutz extension cohort, discontinuation was followed by a return of VAT toward baseline, suggesting that extended or repeated cycles may be relevant to the research question.
REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched tesamorelin across all 7 emirates. Every batch is tested for purity (target ≥99% by HPLC) before dispatch. The cold-chain packaging holds 2-8°C for 24-36 hours — more than enough for any UAE delivery route, including Fujairah and RAK. All shipments use plain, unbranded outer cartons; discreet packaging is the default, not an upsell.
For researchers in Dubai, same-day delivery is available for orders placed before the daily dispatch cut-off. For the rest of the UAE, tesamorelin 24h delivery is standard. Cash on delivery Dubai and across all seven emirates is supported. No pre-payment required if you prefer COD.
| Location | Delivery Window | Cash on Delivery | Discreet Packaging |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, JVC, DIFC, Downtown, Palm, Jumeirah) | Same-day, 4-8 hours | Yes | Yes |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem) | Next-day, 18-24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8-18 hours | Yes | Yes |
| Ajman | Next-day, 18-24 hours | Yes | Yes |
| Ras Al Khaimah (RAK) | Next-day, 18-24 hours | Yes | Yes |
| Fujairah | Next-day, 24 hours | Yes | Yes |
| Umm Al Quwain | Next-day, 18-24 hours | Yes | Yes |
One practical note on ordering volumes: first-time investigators in the UAE often under-order, then experience a supply gap mid-cycle when the peptide is most active. Given that tesamorelin in stock UAE is available now from REVIVE LAB UAE, ordering the full cycle's supply upfront — and storing lyophilized vials at 2-8°C until needed — is the cleaner approach. Reconstitute only what you need for the current 14-day window. To get your order started, visit buy tesamorelin UAE and select your vial format and quantity.
REVIVE LAB UAE stocks tesamorelin in 5 mg and 10 mg lyophilized vials — the two formats consistent with published clinical research. The Falutz et al. pivotal NEJM trials (2007, 2010) and the Stanley et al. NAFLD studies (JAMA 2014, Lancet HIV 2019) all used 2 mg/day subcutaneous as the investigational dose. Investigators beginning shorter observational windows sometimes reference 1 mg/day as a starting research-context dose. No 1 mg or 2 mg vials are stocked — only 5 mg and 10 mg formats, consistent with research supply standards.
Orders placed before the daily dispatch cut-off receive same-day delivery in Dubai — typically 4-8 hours to Dubai Marina, JBR, Business Bay, JVC, DIFC, Downtown, Palm Jumeirah and Jumeirah. Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain are covered under tesamorelin 24h delivery. All vials are dispatched in validated cold-chain insulated packaging. Tesamorelin same day Dubai is the norm for in-emirate orders, not the exception.
Yes. Cash on delivery Dubai is available, as is COD across all seven UAE emirates. All tesamorelin shipments use plain, unbranded outer packaging by default. HPLC purity certificates and lot-COA documentation are available on request for every batch. REVIVE LAB UAE does not require pre-payment for COD orders; researchers can pay the courier on delivery.